BriefMD

Specialties / Hematology

New Hematology research.

The strongest recent Hematology papers on PubMed, ranked by study design, topic and journal, with the same summaries subscribers get.

  1. randomized trial, 207 patients

    Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

    Andemariam B, Kuo KHM, Algahtani FH, et al. Lancet. Oct 2026.

    Findings
    In the trial, 56 (41%) of 138 mitapivat‑treated patients achieved a ≥1 g/dL hemoglobin increase versus 2 (3%) of 69 on placebo, and the annualised pain crisis rate was 2·6 versus 3·1 per year.
    Bottom line
    Mitapivat yields a 38% higher hemoglobin response rate (56/138 vs 2/69) without significantly reducing pain crises.

    PubMed, PMID 42913682

  2. randomized trial, 78 patients

    Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial

    Koschmieder S, Isfort S, Teichmann LL, et al. Blood Cancer J. Oct 2026.

    Findings
    The trial showed clinico‑hematologic complete response rates of 2.3% with ruxolitinib versus 2.9% with best available therapy (p = 1.000), while time on treatment was longer for ruxolitinib (p < 0.001).
    Bottom line
    Ruxolitinib does not increase CR rates (2.3% vs 2.9%) but provides longer treatment exposure (p < 0.001).

    PubMed, PMID 42918761

  3. randomized trial, 66 patients

    Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial

    Valerii MC, Dussias NK, Perri A, et al. Eur J Nutr. Oct 2026.

    Findings
    Serum ferritin rose significantly in both the alternate‑day 21 mg and daily 30 mg iron groups (p < 0.001) with comparable improvements in other iron parameters, while hemoglobin stayed stable.
    Bottom line
    Reduced‑dose alternate‑day iron improves ferritin similarly to daily iron (p < 0.001) and is well tolerated.

    PubMed, PMID 42927507

  4. randomized trial, 76 patients

    Optimization of Anticoagulation Strategy During Cardiopulmonary Bypass in Neonates with Congenital Heart Disease: A Randomized Controlled Trial

    Wang H, Liu Q, Gao P, et al. Drug Des Devel Ther. Jan 2026.

    Findings
    In a randomized controlled trial, 76 neonates undergoing cardiopulmonary bypass were assigned to receive an initial heparin dose of either 600 U/kg (n = 38) or 400 U/kg (n = 38).
    Bottom line
    Both dosing groups included 38 participants, with total enrollment of 76 neonates.

    PubMed, PMID 42899169

  5. randomized trial, 563 patients

    Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High-Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial

    Feng NL, Doering J, Wang TF, et al. Cancer Med. Nov 2026.

    Findings
    Apixaban significantly lowered VTE rates across regimens, including platinum (HR 0.30, 95% CI 0.16-0.57) and taxane regimens (HR 0.42, 95% CI 0.23-0.75). Placebo-treated platinum patients had heightened VTE risk (HR 2.25, 95% CI 1.48-3.42).
    Bottom line
    Apixaban provides consistent thromboprotection without increased bleeding across common chemotherapy classes, especially in high-risk platinum recipients.

    PubMed, PMID 42928572

Summaries are written by AI from PubMed abstracts, for keeping up with the literature. Check the source before it changes care. Editorial policy · Medical disclaimer

Get Hematology research every morning.

Free. Choose your Hematology topics after you subscribe.